← Leaderboards
Susan P Perrine
Boston University Medical Campus
$12,101,972
Attributed
$16,127,960
Total exposure
22
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$16,127,960 · 21
FDA$0 · 1
By mechanism
R01$5,495,840 · 3
R33$5,206,823 · 1
R41$1,966,264 · 6
R42$1,287,476 · 2
R44$991,591 · 1
U54$694,377 · 1
Top collaborators
- Douglas V Faller3 shared
- Kevin Kuo3 shared
- Sylvia T Singer3 shared
- Robert Michael Williams1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Douglas V Faller$14,088,389
- Martin Steinberg$23,614
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaThalassemiaOralGenesAdultClinical TrialsPharmaceutical PreparationsHydroxyureaErythroidInfancyGlobinResponseButyratesMedicalCellsHemoglobinHemoglobinopathiesBlood Disorder ChemotherapyGlobal HealthHematological DiseaseDoseHemoglobin FSeveritiesFetal Hemoglobin
Grant awards (45)
Development of a Clinical Hemoglobin Modulator$1,630,002
R33 · FY2022 · HL · contact PI
Development of a Clinical Hemoglobin Modulator$1,843,809
R33 · FY2021 · HL · contact PI
Development of a Clinical Hemoglobin Modulator$1,733,012
R33 · FY2020 · HL · contact PI
Virus-targeted therapeutic for EBV-Associated Malignancies$519,583
R44 · FY2017 · CA · contact PI
Novel HDAC Inhibitors for Treatment of Hemoglobinopathies$241,742
R41 · FY2017 · HL
Virus-targeted therapeutic for EBV-Associated Malignancies$472,008
R44 · FY2016 · CA · contact PI
Novel Globin Gene Modulators$356,048
R01 · FY2016 · DK · contact PI
Development of a clinical hemoglobin modulator$499,996
R42 · FY2015 · HL · contact PI
Novel Globin Gene Modulators$356,048
R01 · FY2015 · DK · contact PI
Development of a clinical hemoglobin modulator$499,996
R42 · FY2014 · HL · contact PI
Novel Globin Gene Modulators$356,048
R01 · FY2014 · DK · contact PI
Novel Globin Gene Modulators$356,048
R01 · FY2013 · DK · contact PI
Topical Therapeutic to Promote Healing of Chronic Wounds$219,306
R41 · FY2013 · GM · contact PI
Next Generation Therapeutics for Hemoglobinopathies$491,254
R41 · FY2012 · HL · contact PI
in vivo Studies of Clinical Stage Globin Modulators$304,344
R41 · FY2011 · HL · contact PI
Virus-Targeted Therapy for Malignancies$288,895
R43 · FY2011 · CA · contact PI
Oral Agents to Stimulate Neutrophil Production$350,566
R41 · FY2010 · HL · contact PI
Novel Globin Gene Modulators$400,077
R01 · FY2007 · DK · contact PI
A Phase II Trial of Hydroxyurea and Pulse Arginine Butyrate$282,636
U54 · FY2007 · HL · contact PI
Novel Globin Gene Modulators$412,026
R01 · FY2006 · DK · contact PI
Oral Therapeutic for Beta-Thalassemia$143,742
R42 · FY2006 · DK · contact PI
A Phase II Trial of Hydroxyurea and Pulse Arginine Butyrate$140,632
U54 · FY2006 · HL · contact PI
PULSE ARGININE BUTYRATE IN SICKLE CELL DISEASE$15,441
M01 · FY2006 · RR · contact PI
TRIAL OF BUTYRATE IN BETA GLOBIN DISORDERS$1,544
M01 · FY2006 · RR · contact PI
Novel Globin Gene Modulators$412,028
R01 · FY2005 · DK
Oral Therapeutic for Beta-Thalassemia$143,742
R42 · FY2005 · DK
A Phase II Trial of Hydroxyurea and Pulse Arginine Butyrate$137,559
U54 · FY2005 · HL
PULSE ARGININE BUTYRATE IN SICKLE CELL DISEASE WITH HYDROXYUREA THERAPY$45,305
M01 · FY2005 · RR
PULSE BUTYRATE &ERYTHROPOIETIN IN BETA THALASSEMIA INTERMEDIA$29,835
M01 · FY2005 · RR
TRIAL OF BUTYRATE IN BETA GLOBIN DISORDERS$2,578
M01 · FY2005 · RR
Erythropoiesis &pulse arginine butyrate in sickle cell$0
R01 · FY2005 · FD
Novel Globin Gene Modulators$412,026
R01 · FY2004 · DK
Pharmacophore-Modeled Screening for HbF-Inducing Agents$359,052
R41 · FY2004 · HL
A Phase II Trial of Hydroxyurea and Pulse Arginine Butyrate$133,550
U54 · FY2004 · HL
Pulse Butyrate &Erythropoietin in Beta Thalassemia Intermedia$98,736
M01 · FY2004 · RR
Arginine Butyrate for Leg Ulcers in Patients with Sickle Cell &Thalassemia$2,170
M01 · FY2004 · RR
Trial of Butyrate in Beta Globin Disorders$1,085
M01 · FY2004 · RR
Novel Globin Gene Modulators$423,394
R01 · FY2003 · DK
FETAL GLOBIN INDUCTION IN BETA THALASSEMIA$447,546
R01 · FY2002 · HL
FETAL GLOBIN INDUCTION IN BETA THALASSEMIA$440,459
R01 · FY2001 · HL
NOVEL GLOBIN GENE MODULATORS$346,758
R01 · FY2001 · DK
PHASE II TRIAL PULSE BUTYRATE AND ERYTHROPOIETIN IN BETA THALASSEMIA INTERMEDIA$0
M01 · FY2001 · RR
FETAL GLOBIN INDUCTION IN BETA THALASSEMIA$433,583
R01 · FY2000 · HL
NOVEL GLOBIN GENE MODULATORS$343,751
R01 · FY2000 · DK
PULSE BUTYRATE AND ERYTHROPOIETIN IN BETA THALASSEMIA$0
M01 · FY2000 · RR